Monday, September 22, 2014

Cynapsus appoints Ernst & Young as auditor

Cynapsus appoints Ernst & Young as auditor

September 19, 2014 by · Leave a Comment 

Tweet The board of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Ernst & Young as auditor for the company, effective immediately, replacing McGovern, Hurley, Cunningham, which resigned at the request of the company. In a statement, Cynapsus said there were no reservations in the former auditor’s reports in connection with the two most recently completed fiscal […]

NOXXON names Don Munoz as CFO

NOXXON names Don Munoz as CFO

September 19, 2014 by · Leave a Comment 

Tweet Closely-held NOXXON Pharma of Germany has appointed Don Munoz to the newly created position of CFO. He will be based at NOXXON’s new subsidiary office in Boston. Before joining NOXXON, Mr. Munoz was head of investment banking at Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare. Previously, […]

Microbix finalist for 2014 business achievement award

Microbix finalist for 2014 business achievement award

September 18, 2014 by · Leave a Comment 

Tweet Microbix Biosystems (TSX:MBX) has been named a finalist for the prestigious Ontario Business Achievement Award sponsored by the Ontario Chamber of Commerce in the Ontario Going Global medium-sized business category. The award honors companies with 50-to-500 employees that have increased exports by 20% or more in one year. This year, Microbix is one of […]

Stifel starts CymaBay Therapeutics at buy

Stifel starts CymaBay Therapeutics at buy

September 18, 2014 by · Leave a Comment 

Tweet Stifel has initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $10 price target, “based on our expectation for meaningful clinical and significant commercial success of lead pipeline candidate, arhalofenate, for the treatment of gout.” Shares of CymaBay closed at $7.41 on Wednesday. “We view CymaBay’s lead product candidate, arhalofenate, as a […]

AbCelex secures financing from Pinetree Capital

AbCelex secures financing from Pinetree Capital

September 18, 2014 by · Leave a Comment 

Tweet Closely-held AbCelex Technologies has closed a $1-million Series A venture capital financing from Pinetree Capital and a private investor. Proceeds will be used to fund continuing research and development of the company’s antibody-based approach to control a number of pathogens in farm animals implicated in a variety of food-borne illnesses. The company anticipates that […]

Response Biomedical names Tony Holler interim CEO

Response Biomedical names Tony Holler interim CEO

September 17, 2014 by · Leave a Comment 

Tweet Response Biomedical (OTCBB:RPBIF; TSX:RBM) has appointed Dr. Anthony Holler, a long time director, to the post of interim CEO, replacing Jeffrey Purvin, who has resigned as president, CEO and a director, effective immediately. In addition, Dr. Barbara Kinnaird has been promoted from VP to COO. Dr. Holler has been a director of Response since […]

Avita gets FDA approval to modify ReCell trial

Avita gets FDA approval to modify ReCell trial

September 16, 2014 by · Leave a Comment 

Tweet Avita Medical(ASX:AVH; OTCQX:AVMXY) has secured FDA approval for extensive changes to a U.S. clinical trial of ReCell, making the trial more accessible to study participants and broadening the scope of use of ReCell to improve market penetration after regulatory approval. The revised clinical program takes advantage of U.S. clinical experience within both the burns […]

Highline Research starts Evotec at buy

Highline Research starts Evotec at buy

September 16, 2014 by · Leave a Comment 

Tweet Highline Research Advisors has initiated coverage of Evotec AG (Frankfurt Stock Exchange:EVT, TecDAX, ISIN: DE0005664809) with a “buy” rating and price target of €4. The stock closed at €3.07 on Monday. Evotec is a German-based drug discovery company operating two segments: a profitable drug discovery services business called EVT Execute that provides early discovery […]

Agile Therapeutics starts Phase 3 Twirla trial

Agile Therapeutics starts Phase 3 Twirla trial

September 16, 2014 by · Leave a Comment 

Tweet Agile Therapeutics (NASDAQ:AGRX) has initiated a Phase 3 study called SECURE (Study to Evaluate Contraceptive Use, Reliability and Effectiveness) to assess the efficacy, safety and tolerability of its investigational once-weekly transdermal contraceptive patch, Twirla. Twirla is a low-dose combined hormonal contraceptive patch, which delivers the active ingredients ethinyl estradiol and levonorgestrel, both of which […]

Study shows hyperosmolarity may impact cataract surgery planning

Study shows hyperosmolarity may impact cataract surgery planning

September 15, 2014 by · Leave a Comment 

Tweet Preliminary results of the TearLab (NASDAQ:TEAR; TSX:TLB) Cataract Study were presented today at the XXXIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). The groundbreaking study evaluated the relationship of a hyperosmolar tear film on keratometry readings.  The study demonstrated that hyperosmolar patients demonstrated a wider variation in keratometry calculations between […]

Next Page »

Email Newsletters with Constant Contact
Google+